Pilot RCT of senolytics in childhood cancer survivors shows design but lacks efficacy data
SEN-SURVIVORS is an open-label pilot trial testing two senolytic regimens (dasatinib plus quercetin, and fisetin alone) in adult survivors of childhood cancer. The study aimed to measure changes in walking speed and blood senescent cell markers (p16^INK4a) at 60 days, with extended follow-up at 150 days. The abstract describes the study design and objectives but reports no results, efficacy measures, or outcomes.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Apr 24, 2026 · Discovered: Sep 16, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- 5 months
- Population
- Adult survivors of childhood cancer
- Primary outcome
- Change in walking speed and senescent cell abundance in blood (p16^INK4A) at 60 days, with extended follow-up at 150 days
- Effect size
- —
- Significance
- Not reported
- Journal
- St. Jude Children's Research Hospital
- Published
- Sep 30, 2026
Sources
Primary source
- St. Jude Children's Research Hospital ↗Clinical trial
Source versions
Assessment history
9/23/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.